Your session is about to expire
← Back to Search
Forimtamig for Multiple Myeloma
Study Summary
This trialwill test a new drug for multiple myeloma in humans with no standard treatment or who cannot tolerate existing therapies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are there any adverse reactions associated with RO7425781 for patients?
"The safety and efficacy of RO7425781 is limited, earning it a score of 1 on our team's scale from 1 to 3. As this medical trial is in its first phase, there are few data points available to assess the drug beyond preliminary studies."
Are there open vacancies for volunteers to join this research project?
"Affirmative, the clinicaltrials.gov website displays that this research trial is actively searching for participants. It was first published on November 11th 2020 and its most recent update occurred on October 18th 2022. This survey needs 400 patients from 2 different sites to be enrolled."
To what extent are individuals being administered treatments in this experiment?
"Affirmative. According to information published on clinicaltrials.gov, this research effort is actively recruiting for 400 participants across two sites and was originally posted in November 11th 2020 with the last update being October 18th 2022."
Share this study with friends
Copy Link
Messenger